In vitro antibacterial activity of doripenem against clinical isolates from French teaching hospitals: proposition of zone diameter breakpoints
Résumé
The aims of the study were to determine the activity of doripenem, a new carbapenem, against a large number of bacterial pathogens and to propose zone diameter breakpoints for clinical categorization in France according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) minimum inhibitory concentration (MIC) breakpoints. The MICs of doripenem were determined by the broth microdilution method against 1,547 clinical isolates from eight French hospitals. The disk diffusion test was performed (10-μg discs) according to the Comité de l'Antibiogramme de la Société Française de Microbiologie (CASFM) method. The MIC (mg/L) values were as follows: methicillin-susceptible (MSSA) (0.03/0.25), methicillin-resistant (MRSA) (1/2), methicillin-susceptible coagulase-negative staphylococci (MSCoNS) (0.03/0.12), methicillin-resistant coagulase-negative staphylococci (MRCoNS) (2/8), (0.016/0.25), viridans group streptococci (0.016/2), β-hemolytic streptococci (≤0.008/≤0.008), (2/4), (128/>128), (0.06/0.25), (0.5/8), (0.25/2), (0.12/0.25), and (0.03/0.06). According to the regression curve, the zone diameter breakpoints were 24 and 19 mm for MICs of 1 and 4 mg/L, respectively. This study confirms the potent activity of doripenem against , , , MSSA, MSCoNS, and respiratory pathogens. According to the EUCAST MIC breakpoints (mg/L) ≤1/>4 for , , and , and ≤1/>1 for streptococci, pneumococci, and , the zone diameter breakpoints could be (mm) ≥24/<19 and ≥24/<24, respectively.
Domaines
BactériologieOrigine | Fichiers produits par l'(les) auteur(s) |
---|